Lasmiditan: First Approval

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

(2019) Peter J Goadsby et al.   BRAIN

Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine

(2019) Erin Gautier Doty et al.   CEPHALALGIA

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN

(2019) John H Krege et al.   CEPHALALGIA

Targeting CGRP and 5‐HT 1F Receptors for the Acute Therapy of Migraine: A Literature Review

(2019) David Moreno‐Ajona et al.   HEADACHE

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials

(2019) Stewart J. Tepper et al.   HEADACHE

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

(2019) Li Shen Loo et al.   JOURNAL OF HEADACHE AND PAIN

Characterization of binding, functional activity and contractile responses of the selective 5‐HT 1F receptor agonist lasmiditan

(2019) Eloísa Rubio‐Beltrán et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)

(2019) Jan Lewis Brandes et al.   CEPHALALGIA

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies

(2019) Messoud Ashina et al.   HEADACHE

Targeted 5-HT1F Therapies for Migraine

(2018) Marta Vila-Pueyo   Neurotherapeutics

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study

(2012) Markus Färkkilä et al.   LANCET NEUROLOGY

Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan

(2010) David L Nelson et al.   CEPHALALGIA

Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial

(2010) Michel D Ferrari et al.   CEPHALALGIA